的表观遗传调节:一种新的机制和治疗策略
Shuang Chen1, Ming Huang1, Da Xu2
1Department of Neurology, Hubei Provincial Hospital of Integrated Chinese and Western Medicine, Hubei University of Chinese Medicine, Wuhan, 430000, China.
Neurochemistry international
|December 25, 2023
概括
表观遗传机制,包括DNA甲基化和非编码RNA,通过影响突触功能和大脑发育,影响. 对这些表观遗传变化的进一步研究可能会导致新的治疗方法和诊断生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 遗传学 是一个
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- 是一种神经系统疾病,由于神经元活动异常而出现反复发作.
- 目前对病发病的理解涉及神经病理过程,但不完整.
- 表观遗传调节,包括DNA甲基化和非编码RNA,在中越来越被认可.
研究的目的:
- 调查表观遗传失调在病发病的作用.
- 探索表观遗传分析的潜力,以确定的生物标志物和治疗标.
主要方法:
- 对的表观遗传机制研究的综述.
- 对相关基因表观遗传调节的分析.
- 检查对突触功能,神经损伤和认知发展的影响.
主要成果:
- 诸如基因组修饰,DNA甲基化和非编码RNA等表观遗传因素都与有关.
- 表观遗传失调会影响患者的突触功能,神经损伤,认知缺陷和大脑发育.
- 表观遗传学在病原和治疗中的确切功能性作用需要进一步探索.
结论:
- 表观遗传失调在的病理生理学中起着重要作用.
- 在发症发生过程中对表观遗传改变的基因进行分析,可能会为的机制提供新的见解.
- 这项研究强调了表观遗传策略在开发诊断生物标志物和治疗干预措施方面的潜力.
相关概念视频
Epigenetic Regulation
31.1K
Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
31.1K
Arteries of the Lower Limbs
191
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
191
Antiepileptic Drugs: GABAergic Pathway Potentiators
412
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
412
Antiepileptic Drugs: Glutamate Antagonists
376
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
376
Antiepileptic Drugs: Potassium Channel Activators
184
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
184
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
307
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
307


